文献速递流行病学与生物统计临床试验与 GCP

2至12岁儿童肥胖综述

Obesity in Children Aged 2 to 12 Years: A Review.
PubMed 文献 · JAMA · 2026-10-21

该综述指出美国2至5岁儿童肥胖率为15%,6至11岁为22%,并与多种慢性病相关。筛查使用BMI,治疗包括强化健康行为与生活方式治疗,药物选择有限,早期识别治疗可能降低成年期疾病风险。

要点

  • 美国2至5岁儿童肥胖率15%,6至11岁22%。
  • 肥胖定义:BMI≥95百分位;重度肥胖:BMI≥95百分位的120%。
  • 强化健康行为与生活方式治疗可降低BMI 0.7。

核心结论

  • 儿童肥胖与高血压等慢性病及生活质量下降相关,早期识别和治疗可能降低成年期2型糖尿病、血脂异常、高血压和死亡风险。

研究设计与样本

  • 综述,纳入美国2至12岁儿童肥胖相关研究。

主要发现

  • 美国2至5岁儿童肥胖率为15%,6至11岁为22%。
  • 与正常体重同龄人相比,肥胖儿童成年后肥胖可能性高5倍。
  • 强化健康行为与生活方式治疗(至少26接触小时,3至12个月)相比未参与者降低BMI 0.7。
  • 利拉鲁肽在6至<12岁儿童随机临床试验中相比安慰剂降低BMI 7.4%。
  • FDA批准用于<12岁儿童的肥胖药物仅司美拉诺肽,适用于特定遗传性肥胖。

关键数值与推荐

  • 肥胖定义:BMI≥95百分位;重度肥胖:BMI≥95百分位的120%。
  • 筛查推荐:从2岁开始使用BMI筛查肥胖。
  • 强化健康行为与生活方式治疗:至少26接触小时,面对面小组或家庭活动,涵盖营养、体育活动和行为改变教育,持续3至12个月。

临床怎么用

  • 从2岁开始使用BMI筛查儿童肥胖。
  • 对肥胖儿童提供强化健康行为与生活方式治疗。
  • 药物治疗选择有限,司美拉诺肽仅用于特定遗传性肥胖。

局限性

  • 药物短期和长期安全性和有效性数据有限。
  • 代谢和减重手术在<12岁儿童中极少使用,证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Obesity affects 15% of children aged 2 to 5 years and 22% of children aged 6 to 11 years in the US. Obesity in children is associated with dyslipidemia, hypertension, metabolic dysfunction-associated steatotic liver disease, and obstructive sleep apnea. Compared with normal-weight peers, children with obesity have lower quality of life and are 5 times more likely to have obesity in adulthood. OBSERVATIONS: Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) is used to identify children at risk for excess adiposity, and guidelines recommend that clinicians screen for obesity using BMI starting at age 2 years. Among children, obesity is defined using standardized age- and sex-specific growth charts, with obesity defined as BMI in the 95th or higher percentile and severe obesity as BMI of 120% or greater of the 95th percentile. Obesity treatment in children includes intensive health behavior and lifestyle treatment, consisting of at least 26 contact hours of face-to-face group or family-based activities that incorporate nutrition, physical activity, and behavior change education delivered to the child and caregivers over a 3- to 12-month period. Intensive health behavior and lifestyle treatment reduces BMI by 0.7 compared with children who do not participate in intensive health behavior and lifestyle treatment. The only obesity pharmacotherapy currently approved by the US Food and Drug Administration (FDA) for children younger than 12 years is setmelanotide, a melanocortin-4 receptor agonist, which is indicated for 3 forms of rare monogenic obesity (LEPR, POMC, and PCSK1 genetic variants), Bardet-Biedl syndrome, and acquired hypothalamic obesity. Liraglutide is currently only FDA approved for youth aged 12 years or older; however, a randomized clinical trial among children aged 6 to younger than 12 years demonstrated that, compared with placebo, liraglutide reduced BMI by 7.4%. Metabolic and bariatric surgery is rarely used in children younger than age 12 years and evidence supporting its use in children is limited. Early identification and treatment of obesity during childhood may reduce risk of type 2 diabetes, dyslipidemia, hypertension, and mortality in adulthood. CONCLUSIONS AND RELEVANCE: Obesity in children is associated with chronic disease, such as hypertension, and with poor quality of life. Evidence-based treatment for obesity in children includes intensive health behavior and lifestyle treatment, and pharmacotherapy may provide additional benefit, although short- and long-term safety and efficacy data are limited. Early identification and treatment of obesity during childhood may reduce risk of type 2 diabetes, dyslipidemia, hypertension, and mortality in adulthood.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Fox CK, Armstrong SC, Kelly AS, et al. Obesity in Children Aged 2 to 12 Years: A Review. JAMA. 2026. PMID: 42905688. doi:10.1001/jama.2026.18806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。